2,539 reports of this reaction
13.3% of all SEVELAMER CARBONATE reports
#1 most reported adverse reaction
CONSTIPATION is the #1 most commonly reported adverse reaction for SEVELAMER CARBONATE, manufactured by Genzyme Corporation. There are 2,539 FDA adverse event reports linking SEVELAMER CARBONATE to CONSTIPATION. This represents approximately 13.3% of all 19,097 adverse event reports for this drug.
Patients taking SEVELAMER CARBONATE who experience constipation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONSTIPATION is a frequently reported adverse event for SEVELAMER CARBONATE, accounting for a significant proportion of all reports.
In addition to constipation, the following adverse reactions have been reported for SEVELAMER CARBONATE:
The following drugs have also been linked to constipation in FDA adverse event reports:
CONSTIPATION has been reported as an adverse event in 2,539 FDA reports for SEVELAMER CARBONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONSTIPATION accounts for approximately 13.3% of all adverse event reports for SEVELAMER CARBONATE, making it one of the most commonly reported side effect.
If you experience constipation while taking SEVELAMER CARBONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.